Past approaches and future directions for targeting tumor hypoxia in squamous cell carcinomas of the head and neck

Critical Reviews in Oncology/Hematology

Volumn 103, Issue , 2016, Pages 86-98

  Curtis, Kelly K ^a   Wong, William W ^b   Ross, Helen J ^a  

^a Division of Hematology Oncology   (United States)

^b MAYO CLINIC   (United States)

Author keywords

Bioreductive drugs; Hypoxia; Radiation sensitivity; Radiotherapy; Squamous cell carcinoma

Indexed keywords

1 FLUORO 3 (2 NITRO 1 IMIDAZOLYL) 2 PROPANOL F 18; BANOXANTRONE; BEVACIZUMAB; CARBOGEN; CETUXIMAB; CISPLATIN; COMBRETASTATIN A4 PHOSPHATE; DOCETAXEL; EVOFOSFAMIDE; FLUOROAZOMYCIN ARABINOSIDE F 18; FLUOROERYTHRONITROIMIDAZOLE F 18; FLUOROETANIDAZOLE F 18; GADOLINIUM PENTETATE MEGLUMINE; GEMCITABINE; GLUCOSE TRANSPORTER 1; HEAT SHOCK PROTEIN 90; HYDROXYCHLOROQUINE; HYPOXIA INDUCIBLE FACTOR 1ALPHA; MAMMALIAN TARGET OF RAPAMYCIN; NICOTINAMIDE; NIMORAZOLE; PENTOXIFYLLINE; PROGRAMMED DEATH 1 LIGAND 1; RADIOPHARMACEUTICAL AGENT; RECOMBINANT ERYTHROPOIETIN; TANESPIMYCIN; TIRAPAZAMINE; TRASTUZUMAB; UNCLASSIFIED DRUG; UNINDEXED DRUG; VON HIPPEL LINDAU PROTEIN; ERYTHROPOIETIN; OXYGEN;

ADVANCED CANCER; BLADDER CANCER; BLOOD TRANSFUSION; BRAIN CANCER; BREAST METASTASIS; CANCER RADIOTHERAPY; CANCER SURVIVAL; CONTRAST ENHANCEMENT; FLUSHING; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; HYPERBARIC OXYGEN; HYPERTHERMIA; HYPOXIA; IMMUNOMODULATION; LARYNX CANCER; NAUSEA; NON SMALL CELL LUNG CANCER; ONCOLOGICAL PARAMETERS; PHARYNX CANCER; RADIOSENSITIVITY; RASH; REVIEW; SIDE EFFECT; SOLID TUMOR; SURVIVAL RATE; SYSTEMATIC REVIEW; TREATMENT OUTCOME; TREATMENT RESPONSE; TUMOR BLOOD FLOW; TUMOR MICROENVIRONMENT; UTERINE CERVIX CANCER; VOMITING; AGONISTS; ANIMAL; CARCINOMA, SQUAMOUS CELL; COMPLICATION; HEAD AND NECK NEOPLASMS; METABOLISM; THERMOTHERAPY; TUMOR HYPOXIA; VASCULARIZATION;

ANIMALS; CARCINOMA, SQUAMOUS CELL; ERYTHROPOIETIN; HEAD AND NECK NEOPLASMS; HUMANS; HYPERTHERMIA, INDUCED; OXYGEN; TUMOR HYPOXIA;

EID: 84969909641     PISSN: 10408428     EISSN: 18790461     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2016.05.005     Document Type: Review

References (170)

1. Alvarez-Tejado M., Naranjo-Suarez S., Jimenez C., et al. Hypoxia induces the activation of phosphatidylinositol 3-kinase/Akt cell survival pathway in PC12 cells: protective role in apoptosis. J. Biol. Chem. 2001, 276:22368-22374.
2. Aviado D.M., Porter J.M. Pentoxifylline: a new drug for the treatment of intermittent claudication Mechanism of action, pharmacokinetics, clinical efficacy and adverse effects. Pharmacotherapy 1984, 4:297-307.
3. Bache M., Kappler M., Said H.M., et al. Detection and specific targeting of hypoxic regions within solid tumors: current preclinical and clinical strategies. Curr. Med. Chem. 2008, 15:322-338.
4. Baer S., Casaubon L., Schwartz M.R., et al. Glut3 expression in biopsy specimens of laryngeal carcinoma is associated with poor survival. Laryngoscope 2002, 112:393-396.
5. Baginska J., Viry E., Paggetti J., et al. The critical role of the tumor microenvironment in shaping natural killer cell-mediated anti-tumor immunity. Front. Immunol. 2013, 4:490. eCollection 2013. Review.
6. Baluk P., Morikawa S., Haskell A., et al. Abnormalities of basement membrane on blood vessels and endothelial sprouts in tumors. Am. J. Pathol. 2003, 163:1801-1815.
7. Barsoum I.B., Smallwood C.A., Siemens D.R., et al. A mechanism of hypoxia-mediated escape from adaptive immunity in cancer cells. Cancer Res. 2014, 74:665-674.
8. Beasley N.J., Wykoff C.C., Watson P.H., et al. Carbonic anhydrase IX, an endogenous hypoxia marker, expression in head and neck squamous cell carcinoma and its relationship to hypoxia, necrosis, and microvessel density. Cancer Res. 2001, 61:5262-5267.
9. Beavis P.A., Divisekera U., Paget C., et al. Blockade of A2AA receptor potently suppresses the metastasis of CD73+ tumors. Proc. Natl. Acad. Sci. U. S. A. 2013, 110:14711-14716.
10. Bennett M., Feldmeier J., Smee R., et al. Hyperbaric oxygen for tumour sensitisation to radiotherapy. Cochrane Database Syst. Rev. 2005, CD005007.
11. Clinicaltrials.gov. [Internet] Bethesda (MD): National Library of Medicine (US) 2000 Feb 29 -. Identifier NCT 00394628. AQ4N in combination with radiotherapy and temozolomide in subjects with newly diagnosed glioblastoma multiforme. 2007, May 29 [cited 2014 May 12]. Available from. http://www.clinicaltrials.gov/ct2/show/NCT00394628%3Fterm=banoxantrone%26rank=1.
12. Clinicaltrials.gov. [Internet] Bethesda (MD): National Library of Medicine (US) 2000 Feb 29 -. Identifier NCT 01266057. Sirolimus or vorinostat and hydroxychloroquine in advanced cancer. 2010, Dec 22 [cited 2015 Mar 2]. Available from. http://https://www.clinicaltrials.gov/ct2/results%3Fterm=hydroxychloroquine+and+cancer%26recr=Open.
13. Clinicaltrials.gov. [Internet] Bethesda (MD): National Library of Medicine (US) 2000 Feb 29 -. Identifier NCT 01507467. IAEA-HypoX. Accelerated radiotherapy with or without nimorazole in squamous cell carcinoma of the head and neck. 2011, Aug 14 [cited 2016 Mar 21]. Available from:. http://www.clinicaltrials.gov/ct2/show/NCT01507467%3Fterm=NCT+01507467%26rank=1.
14. Clinicaltrials.gov. [Internet] Bethesda, (MD): National Library of Medicine (US) 2000 Feb 29-. Identifier NCT 01827709. Pathological validation of functional imaging in head and neck squamous cell carcinoma. 2013, Mar 27 [cited 2016 Mar 21]. Available from. http://www.clinicaltrials.gov/ct2/results%3Fterm=NCT+01827709%26Search=Search.
15. Betts G.N., Eustace A., Patiar S., et al. Prospective technical validation and assessment of intra-tumour heterogeneity of a low density array hypoxia gene profile in head and neck squamous cell carcinoma. Eur. J. Cancer 2013, 49:156-165.
16. Bingle L., Brown N.J., Lewis C.E. The role of tumour-associated macrophages in tumour progression: implications for new anticancer therapies. J. Pathol. 2002, 196:254-265.
17. Bleumer I., Knuth A., Oosterwijk E., et al. A phase II trial of chimeric monoclonal antibody G250 for advanced renal cell carcinoma patients. Br. J. Cancer 2004, 90:985-990.
18. Bleumer I., Oosterwijk E., Oosterwijk-Wakka J.C., et al. A clinical trial with chimeric monoclonal antibody WX-G250 and low dose interleukin-2 pulsing scheme for advanced renal cell carcinoma. J. Urol. 2006, 175:57-62.
19. Blohmer J.U., Rezai M., Kummel S., et al. Using the 21-gene assay to guide adjuvant chemotherapy decision-making in early-stage breast cancer: a cost-effectiveness evaluation in the German setting. J. Med. Econ. 2013, 16:30-40.
20. 18FAZA PET/CT in head and neck and lung cancer patients during chemoradiation: possible implications for radiotherapy treatment planning strategies. Radiother. Oncol. 2014, 113:198-203.
21. Bozec C., Sudaka A., Fischel J.L., et al. Combined effects of bevacizumab with erlotinib and radiation: a preclinical study on a head and neck orthotopic model. Br. J. Cancer 2008, 99:93-99.
22. Brown J. Evidence for acutely hypoxic cells in mouse tumours, and a possible mechanism of reoxygenation. Br. J. Radiol. 1979, 52:650-656.
23. Buffa F.M., Harris A.L., West C.M., et al. Large meta-analysis of multiple cancers reveals a common, compact and highly prognostic hypoxia metagene. Br. J. Cancer 2010, 102:428-435.
24. Bydder P.V., Burry A.F., Gowland S., et al. A controlled trial of misonidazole in the curative treatment of infiltrating bladder cancer. Australas. Radiol. 1989, 33:8-14.
25. Carmeliet P., Jain K.K. Principles and mechanisms of vessel normalization for cancer and other angiogenic diseases. Nat. Rev. Drug Discov. 2011, 10:417-427.
26. Ching L.M., Cao Z., Kieda C., et al. Induction of endothelial cell apoptosis by the antivascular agent 5,6-dimethylxanthenone-4-acetic acid. Br. J. Cancer 2002, 86:1937-1942.
27. Chitneni S.K., Palmer G.M., Zalutsky M.R., et al. Molecular imaging of hypoxia. J. Nucl. Med. 2011, 52:165-168.
28. Clatot F., Gouerant S., Mareschal S., et al. The gene expression profile of inflammatory, hypoxic and metabolic genes predicts the metastatic spread of human head and neck squamous cell carcinoma. Oral Oncol. 2014, 50:200-207.
29. Datta N.R., Bose A.K., Kapoor H.K., et al. Head and neck cancers: results of thermoradiotherapy versus radiotherapy. Int. J. Hypertherm. 1990, 6:479-486.
30. Deng B., Zhu J.M., Wang Y., et al. Intratumor hypoxia promotes immune tolerance by inducing regulatory T cells via TGF-beta1 in gastric cancer. PLoS One 2013, 8:e63777.
31. Dewhirst M.W., Cao Y., Moeller B. Cycling hypoxia and free radicals regulate angiogenesis and radiotherapy response. Nat. Rev. Cancer 2008, 8:425-437.
32. DiSilvestro P.A., Ali S., Craighead P.S., et al. Phase III randomized trial of weekly cisplatin and irradiation versus cisplatin and tirapazamine and irradiation in stages IB2, IIA, IIB, IIIB, and IVA cervical carcinoma limited to the pelvis: a Gynecology Oncology Group study. J. Clin. Oncol. 2014, 32:458-464.
33. Doubrovina E.S., Doubrovin M.M., Vider E., et al. Evasion from NK cell immunity by MHC class I chain-related molecules expressing colon adenocarcinoma. J. Immunol. 2003, 171:6891-6899.
34. Dvorak H.F., Nagy J.A., Dvorak J.K., et al. Identification and characterization of the blood vessels of solid tumors that are leaky to circulating macromolecules. Am. J. Pathol. 1988, 133:95-109.
35. Ellinghaus P., Heisler I., von Ahsen O., et al. BAY87-2243 targets hypoxia-induced activation and stabilization of HIF-1α: a novel approach to overcome resistance mechanisms in cancer therapy [abstract]. Cancer Res. 2011, 71(Suppl (8)):4509.
36. Evans S.M., Du K.L., Chalian A.A., et al. Patterns and level of hypoxia in head and neck squamous cell carcinomas and their relationship to patient outcome. Int. J. Radiat. Oncol. Biol. Phys. 2007, 69:1024-1031.
37. Falchook G.S., Wheler J.J., Naing A., et al. Targeting hypoxia-inducible factor-1α (HIF-1α) in combination with antiangiogenic therapy: a phase I trial of bortezomib plus bevacizumab. Oncotarget 2014, 5:10280-10292.
38. Fury M.G., Lee N.Y., Sherman E.J., et al. A phase 2 study of bevacizumab with cisplatin plus intensity-modulated radiation therapy for stage III/IVB head and neck squamous cell cancer. Cancer 2012, 118:5008-5014.
39. Fury M.G., Xiao H., Sherman E.J., et al. Phase II trial of bevacizumab + cetuximab + cisplatin with concurrent intensity modulated radiation for patients with stage III/IVB head and neck squamous cell carcinoma. Head Neck 2015, Epub ahead of print.
40. Ganjoo K.N. New developments in targeted therapy for soft tissue sarcoma. Curr. Oncol. Rep. 2010, 12:261-265.
41. Ghiringhelli F., Menard C., Terme M., et al. CD4 + CD25+ regulatory T cells inhibit natural killer cell functions in a transforming growth factor-beta-dependent manner. J. Exp. Med. 2005, 202:1075-1085.
42. Glaser C.M., Millesi W., Kornek G.V., et al. Impact of hemoglobin level and use of recombinant erythropoietin on efficacy of preoperative chemoradiation therapy for squamous cell carcinoma of the oral cavity and oropharynx. Int. J. Radiat. Oncol. Biol. Phys. 2001, 50:705-715.
43. Gray L.H., Conger A.D., Ebert M., et al. The concentration of oxygen dissolved in tissues at the time of irradiation as a factor in radiotherapy. Br. J. Radiol. 1953, 26:638-648.
44. 18F-labelled tracers: biology meets technology. Eur. J. Nucl. Med. Mol. Imaging 2007, 34:1563-1565.
45. Gronroos T.J., Lehtio K., Sonderstrom K.O., et al. Hypoxia, blood flow and metabolism in squamous-cell carcinoma of the head and neck: correlations between multiple immunohistochemical parameters and PET. BMC Cancer 2014, 14:876.
46. Hall E. Radiobiology for the radiologist 2000, JB Lippincott, Philadelphia. 5th ed.
47. Hart, C., Meng, F., Banica, M., et al. In vitro activity profile of the novel hypoxia-activated cytotoxic prodrug TH-302 [abstract]. AACR Meeting Abstracts 2008. 2008; 1441.
48. Hausler S.F., Montalban del Barrio I., Strohschein J., et al. Ectonucleotidases CD39 and CD73 on OvCA cells are potent adenosine-generating enzymes responsible for adenosine receptor 2A-dependent suppression of T cell function and NK cell cytotoxicity. Cancer Immunol. Immunother. 2011, 60:1405-1458.
49. Heath E.I., Hillman D.W., Vaishampayan U., et al. A phase II trial of 17-allylamino-17-demethoxygeldanamycin in patients with hormone-refractory metastatic prostate cancer. Clin. Cancer Res. 2008, 14:7940-7946.
50. Henke M., Laszig R., Rube C., et al. Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomized, double-blind, placebo-controlled trial. Lancet 2003, 362:1255-1260.
51. Hill R.P., Bush R.S., Yeung P. The effect of anaemia on the fractionation of hypoxic cells in an experimental tumour. Br. J. Radiol. 1971, 44:299-304.
52. Hirst D.G., Wood P.J. The adaptive response of mouse tumours to anaemia and retransfusion. Int. J. Radiat. Biol. Relat. Stud. Phys. Chem. Med. 1987, 51:597-609.
53. Hoang T., Huang S., Armstrong E., et al. Enhancement of radiation response with bevacizumab. J. Exp. Clin. Cancer Res. 2012, 31:37.
54. Hodi F.S., O'Day S.J., McDermott D.F., et al. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 2010, 363:711-723.
55. Hoff C.M., Hansen H.S., Overgaard M., et al. The importance of haemoglobin level and effect of transfusion in HNSCC patients treated with radiotherapy-results from the randomized DAHANCA 5 study. Radiother. Oncol. 2011, 98:28-33.
56. Hoff C.M., Lassen P., Eriksen J.G., et al. Does transfusion improve the outcome for HNSCC patients treated with radiotherapy? -results from the randomized DAHANCA 5 and 7 trials. Acta Oncol. 2011, 50:1006-1014.
57. Hoogsteen I.J., Marres H.A., Bussink J., et al. Tumor microenvironment in head and neck squamous cell carcinomas: predictive value and clinical relevance of hypoxic markers. A review. Head Neck. 2007, 29:591-604.
58. Horsman H.R., Overgaard J. Hyperthermia: a potent enhancer of radiotherapy. Clin. Oncol. (R. Coll. Radiol.) 2007, 19:418-426.
59. Horsman M.R., Siemann D.W., Chaplin D.J., et al. Nicotinamide as a radiosensitizer in tumours and normal tissues: the importance of drug dose and timing. Radiother. Oncol. 1997, 45:167-174.
60. Horsman M.R. Angiogenesis and vascular targeting: relevance for hyperthermia. Int. J. Hyperthermia 2008, 24:57-65.
61. Hu K., Harrison L.B. Impact of anemia in patients with head and neck cancer treated with radiation therapy. Curr. Treat. Options Oncol. 2005, 6:31-45.
62. Hudson C.C., Liu M., Chiang G.G., et al. Regulation of hypoxia-inducible factor 1alpha expression and function by the mammalian target of rapamycin. Mol. Cell. Biol. 2002, 22:7004-7014.
63. Huilgol N.G., Gupta S., Sridhar C.R. Hyperthermia with radiation in the treatment of locally advanced head and neck cancer: a report of a randomized trial. J. Cancer Res. Ther. 2010, 6:492-496.
64. Hurwitz M.D. Today's thermal therapy: not your father's hyperthermia: challenges and opportunities in application of hyperthermia for the 21st century cancer patient. Am. J. Clin. Oncol. 2010, 33:96-100.
65. Isaacs J.S., Jung Y.J., Mimnaugh E.G., et al. Hsp90 regulates a von Hippel Lindau-independent hypoxia-inducible factor-1 alpha-degradative pathway. J. Biol. Chem. 2002, 277:29936-29944.
66. 18F-fluoromisonidazole positron emission tomography imaging in neck nodal metastases. Int. J. Radiat. Oncol. Biol. Phys. 2010, 77:1403-1410.
67. Janssen H.L., Haustermans K.M., Balm A.J., et al. Hypoxia in head and neck cancer: how much, how important?. Head Neck 2005, 27:622-638.
68. Janssens G.O., Terhaard C.H., Doornaert P.A., et al. Acute toxicity profile and compliance to accelerated radiotherapy plus carbogen and nicotinamide for clinical stage T2-T4 laryngeal cancer: results of a phase III randomized trial. Int. J. Radiat. Oncol. Biol. Phys. 2011, (February). [Epub ahead of print].
69. Janssens G.O., Rademakers S.E., Terhaard C.H., et al. Accelerated radiotherapy with carbogen and nicotinamide for laryngeal cancer: results of a phase III randomized trial. J. Clin. Oncol. 2012, 30:1777-1783.
70. Janssens G.O., Rademakers S.E., Terhaard C.H., et al. Improved recurrence-free survival with ARCON for larynx cancer patients with anemia. Clin. Cancer Res. 2014, Epub ahead of print.
71. Jiang B.H., Jiang G., Zheng J.Z., et al. Phosphatidylinositol 3-kinase signaling controls levels of hypoxia-inducible factor 1. Cell Growth Differ. 2001, 12:363-369.
72. Johnson F.E., Harrison B.R., McKirgan L.W., et al. A phase II evaluation of pentoxifylline combined with radiation in the treatment of brain metastases. Int. J. Oncol. 1998, 13:801-805.
73. Jordan B.F., Runquist M., Raghunand N., et al. Dynamic contrast-enhanced and diffusion MRI show rapid and dynamic changes in tumor microenvironment in response to inhibition of HIF-1alpha using PX-478. Neoplasia 2005, 7:475-485.
74. Kaanders J.H., Pop L.A., Marres H.A., et al. Accelerated radiotherapy with carbogen and nicotinamide (ARCON) for laryngeal cancer. Radiother. Oncol. 1998, 48:115-122.
75. Kaanders J.H., Bussink J., van der Kogel A.J. ARCON: a novel biology-based approach in radiotherapy. Lancet Oncol. 2002, 3:728-737.
76. Kaanders J.H., Pop L.A., Marres H.A., et al. ARCON: experience in 215 patients with advanced head-and-neck cancer. Int. J. Radiat. Oncol. Biol. Phys. 2002, 52:769-778.
77. Kaanders J.H., Wijffels K.I., Marres H.A., et al. Pimonidazole binding and tumor vascularity predict for treatment outcome in head and neck cancer. Cancer Res. 2002, 62:7066-7074.
78. Kallman R.F. The phenomenon of reoxygenation and its implications for fractionated radiotherapy. Radiology 1972, 105:135-142.
79. Kaluz S., Kaluzova M., Liao S.Y., et al. Transcriptional control of the tumor- and hypoxia-marker carbonic anhydrase 9: a one transcription factor (HIF-1) show?. Biochim. Biophys. Acta 2009, 1795:162-172.
80. Kaplan H. Historic milestones in radiobiology and radiation therapy. Semin. Oncol. 1979, 6:479-489.
81. Kikuchi M., Yamane T., Shinohara S., et al. 18F-fluoromisonidazole positron emission tomography before treatment is a predictor of radiotherapy outcome and survival prognosis in patients with head and neck squamous cell carcinoma. Ann. Nucl. Med. 2011, 25:625-633.
82. Kjellen E., Sasaki Y., Kjellstrom J., et al. Recombinant erythropoietin beta enhances growth of xenografted human squamous cell carcinoma of the head and neck after surgical trauma. Acta Otolaryngol. 2006, 126:545-547.
83. Kong C.S., Narasimhan B., Cao H., et al. The relationship between human papillomavirus status and other molecular prognostic markers in head and neck squamous cell carcinomas. Int. J. Radiat. Oncol. Biol. Phys. 2009, 74:553-561.
84. Koumenis C., Wouters B.G. Translating tumor hypoxia: unfolded protein response (UPR)-dependent and UPR-independent pathways. Mol. Cancer Res. 2006, 4:423-436.
85. Krause B.J., Beck R., Souvatzoglou M., et al. PET and PET/CT studies of tumor oxygenation. Q. J. Nucl. Med. Mol. Imaging 2006, 50:2-43.
86. Kruser T.J., Wheeler D.L., Armstrong E.A., et al. Augmentation of radiation response by motesanib, a multikinase inhibitor that targets endothelial growth factor receptors. Clin. Cancer Res. 2010, 16:3639-3647.
87. Kuhnert F., Kirshner J.R., Thurston G. Dll0034-notch signaling as a therapeutic target in tumor angiogenesis. Vasc. Cell. 2011, 3:20-28.
88. Kwon H.C., Kim S.K., Chung W.K., et al. Effect of pentoxifylline on radiation response of non-small cell lung cancer: a phase III randomized multicenter trial. Radiother. Oncol. 2000, 56:175-179.
89. Lambin P., Ramaekers B.L.T., van Mastrigt G.A.P.G., et al. Erythropoietin as an adjuvant treatment with (chemo)radiation therapy for head and neck cancer. Cochrane Database Syst. Rev. 2009, CD0 06158.
90. Lassen P., Eriksen J.G., Hamilton-Dutoit S., et al. HPV-associated p16-expression and response to hypoxic modification of radiotherapy in head and neck cancer. Radiother. Oncol. 2010, 94:30-35.
91. Lee D.J., Cosmatos D., Marcial V.A., et al. Results of an RTOG phase III trial (RTOG 85-27) comparing radiotherapy plus etanidazole with radiotherapy alone for locally advanced head and neck carcinomas. Int. J. Radiat. Oncol. Biol. Phys. 1995, 32:567-576.
92. Lee C.P., Payne G.S., Oregioni A., et al. A phase I study of the nitroimidazole hypoxia marker SR455r using 19F magnetic resonance spectroscopy. Br. J. Cancer 2009, 101:1860-1868.
93. Lee C.T., Mace T., Repasky E.A. Hypoxia-driven immunosuppression: a new reason to use thermal therapy in the treatment of cancer?. Int. J. Hyperthermia 2010, 26:232-246.
94. Lehtio K., Eskola O., Viljanen T., et al. Imaging perfusion and hypoxia with PET to predict radiotherapy response in head-and-neck cancer. Int. J. Radiat. Oncol. Biol. Phys. 2004, 59:971-982.
95. Li L., Rojiani A., Siemann D.W. Targeting the tumor vasculature with combretastatin A-4 disodium phosphate: effects on radiation therapy. Int. J. Radiat. Oncol. Biol. Phys. 1998, 42:899-903.
96. Lin Y.T., Chuang H.C., Chen C.H., et al. Clinical significance of erythropoietin receptor expression in oral squamous cell carcinoma. BMC Cancer 2012, 12:194.
97. Lokshin A., Raskovalova T., Huang X., et al. Adenosine-mediated inhibition of the cytotoxic activity and cytokine production by activated natural killer cells. Cancer Res. 2006, 66:7758-7765.
98. Machtay M., Pajak T.F., Suntharalingam M., et al. Radiotherapy with or without erythropoietin for anemic patients with head and neck cancer: a randomized trial of the Radiation Oncology Therapy Group (RTOG 99-03). Int. J. Radiat. Oncol. Biol. Phys. 2007, 69:1008-1017.
99. Masunaga S., Liu Y., Tanaka H., et al. Reducing intratumor acute hypoxia through bevacizumab treatment, referring to the response of quiescent tumor cells and metastatic potential. Br. J. Radiol. 2011, 84:1131-1138.
100. McCormick C.C., Li W.P., Calero M. Oxygen tension limits nitric oxide synthesis by activated macrophages. Biochem. J 2000, 350(Pt 3):709-716.
101. McKeage M.J., Baguley B.C. Disrupting established tumor blood vessels: an emerging therapeutic strategy for cancer. Cancer 2010, 116:1859-1871.
102. McKeage M.J., von Pawel J., Reck M., et al. Randomised phase II study of ASA404 combined with carboplatin and paclitaxel in previously untreated advanced non-small cell lung cancer. Br. J. Cancer 2008, 99:2006-2012.
103. McKeage M.J., Gu Y., Wilson W.R., et al. A phase I trial of PR-104, a pre-prodrug of the bioreductive prodrug PR-104A, given weekly to solid tumor patients. BMC Cancer 2011, 11:432.
104. McKeage M.J., Jameson M.B., Ramanathan R.K., et al. PR-104 a bioreductive pre-prodrug combined with gemcitabine or docetaxel in a phase Ib study of patients with advanced solid tumors. BMC Cancer 2012, 12:496.
105. Minet E., Mottet D., Michel G., et al. Hypoxia induced activation of HIF-1: role of HIF-1alpha-Hsp90 interaction. FEBS Lett. 1999, 460:251-256.
106. Mineta H., Miura K., Takebayashi S., et al. Prognostic value of glucose transporter 1 expression in patients with hypopharyngeal carcinoma. Anticancer Res. 2002, 22:3489-3494.
107. Modi S., Stopeck A.T., Linden H.M., et al. HSP90 inhibition is effective in breast cancer: a phase 2 trial of tanespimycin (17AAG) plus trastuzumab in patients with HER2-positive metastatic breast cancer progressing on trastuzumab. Clin. Cancer Res. 2011, 17:5132-5139.
108. Moulder J., Rockwell S. Hypoxic fractions of solid tumors: experimental techniques, methods of analysis and a survey of existing data. Int. J. Radiat. Oncol. Biol. Phys. 1984, 10:695-712.
109. Murata R., Siemann D.W., Overgaard J., et al. Improved tumor response by combining radiation and the vascular-damaging drug 5,6-dimethylxanthenone-4-acetic acid. Radiat. Res. 2001, 156:503-509.
110. Nijkamp M.M., Span P.N., Terhaard C.H.J., et al. Epidermal growth factor receptor expression in laryngeal cancer predicts the effect of hypoxia modification as an additive to accelerated radiotherapy in a randomized controlled trial. Eur. J. Cancer 2013, 49:3202-3209.
111. Nordsmark M., Bentzen S.M., Rudat V., et al. Prognostic value of tumor oxygenation in 397 head and neck tumors after primary radiation therapy. An international multi-center study. Radiother. Oncol. 2005, 77:18-24.
112. Norikane T., Yamamoto Y., Maeda Y., et al. Correlation of (18)F-fluoromisonidazole PET findings with HIF-1α and p53 expression in head and neck cancer: comparison with (18)F-FDG PET. Nucl. Med. Commun. 2014, 35:30-35.
113. Nyflot M.J., Kruser T.J., Traynor A.M., et al. Phase 1 trial of bevacizumab with concurrent chemoradiation therapy for squamous cell carcinoma of the head and neck with exploratory functional imaging of tumor hypoxia, proliferation and perfusion. Int. J. Radiat. Oncol. Biol. Phys. 2015, (February). [Epub ahead of print].
114. Ohta A., Gorelik E., Sj Prasad, et al. A2A adenosine receptor protects tumors from antitumor T cells. Proc. Natl. Acad. Sci. U. S. A. 2006, 103:13132-13137.
115. Overgaard J., Hansen H.S., Overgaard M., et al. A randomized double-blind phase III study of nimorazole as a hypoxic radiosensitizer of primary radiotherapy in supraglottic larynx and pharynx carcinoma. Results of the Danish head and neck cancer study (DAHANCA) protocol 5-85. Radiother. Oncol. 1998, 46:135-146.
116. Overgaard J. Hypoxic radiosensitization: adored and ignored. J. Clin. Oncol. 2007, 25:4066-4074.
117. Overgaard J. Hypoxic modification of radiotherapy in squamous cell carcinoma of the head and neck -a systematic review and meta-analysis. Radiother. Oncol. 2011, 100:22-32.
118. Pacheco-Torres J., Lopez-Larrubia Ballesteros P., et al. Imaging tumor hypoxia by magnetic resonance methods. NMR Biomed. 2011, 24:1-16.
119. Panther E., Corinti S., Idzko M., et al. Adenosine affects expression of membrane molecules, cytokine and chemokine release, and the T-cell stimulatory capacity of human dendritic cells. Blood 2003, 101:3985-3990.
120. Papadopoulos K.P., Goel S., Beeram M., et al. A phase 1 open-label, accelerated dose-escalation study of the hypoxia-activated prodrug AQ4 N in patients with advanced malignancies. Clin. Cancer Res. 2008, 14:7110-7115.
121. Papandreou L., Lim A.L., Laderoute K., et al. Hypoxia signals autophagy in tumor cells via AMPK activity, independent of HIF-1, BNIP3, and BNIP3L. Cell Death Differ. 2008, 15:1572-1581.
122. Pastorekova S., Zatovicova M., Pastorek J. Cancer-associated anhydrases and their inhibition. Curr. Pharm. Des. 2008, 14:685-698.
123. Pencreach E., Guerin E., Nicolet C., et al. Marked activity of irinotecan and rapamycin combination toward colon cancer cells in vivo and in vitro is mediated through cooperation of modulation of the mammalian target of rapamycin/hypoxia-inducible factor-1alpha axis. Clin. Cancer Res. 2009, 15:1297-1307.
124. Peters L., Rischin D. Elusive goal of targeting tumor hypoxia for therapeutic gain. J. Clin. Oncol. 2012, 30:1741-1743.
125. Powers W.E., Tolmach L.J. A multicomponent x-ray survival curve for mouse lymphosarcoma cells irradiated. Nature 1963, 197:710-711.
126. Powis G., Kirkpatrick L. Hypoxia inducible factor 1-alpha as a cancer drug target. Mol. Cancer Ther. 2004, 3:647-654.
127. 19F magnetic resonance spectroscopy and chemical shift imaging of tri-fluoro-nitroimidazole as a potential hypoxia reporter in solid tumors. Clin. Cancer Res. 2007, 13:3738-3747.
128. Rajendran J.G., Schwartz D.L., O'sullivan J., et al. Tumor hypoxia imaging with [F-18] fluoromisonidazole positron emission tomography in head and neck cancer. Clin. Cancer Res. 2006, 12:5435-5441.
129. 18F]fluoromisonidazole: a pretherapy study of 37 patients. Int. J. Radiat. Oncol. Biol. Phys. 1996, 36:417-428.
130. Raskovalova T., Huang X., Sitkovsky M., et al. Gs protein-coupled adenosine receptor signaling and lytic function of activated NK cells. J. Immunol. 2005, 175:4383-4391.
131. Ribatti M., Presta M., Vacca A., et al. Human erythropoietin induces a pro-angiogenic phenotype in cultured endothelial cells and stimulates neovascularization in vivo. Blood 1999, 93:2627-2636.
132. Rischin D., Peters L.J., O'sullivan B., et al. Tirapazamine, cisplatin, and radiation versus cisplatin and radiation for advanced squamous cell carcinoma of the head and neck (TROG 02.02, HeadSTART): a phase III trial of the Trans-Tasman Radiation Oncology Group. J. Clin. Oncol. 2010, 28:2989-2995.
133. Rosen F.R., Haraf D.J., Kies M.S., et al. Multicenter randomized phase II study of paclitaxel (1-hour infusion), fluorouracil, hydroxyurea, and concomitant twice daily radiation with or without erythropoietin for advanced head and neck cancer. Clin. Cancer Res. 2003, 9:1689-1697.
134. Roth J.A., Billings P., Ramsey S.D., et al. Cost-effectiveness of a 14-gene risk score assay to target adjuvant chemotherapy in early stage non-squamous non-small cell lung cancer. Oncologist 2014, (April). [Epub ahead of print].
135. 2 histography in patients with advanced head and neck cancer. Radiother. Oncol. 2000, 57:31-37.
136. 2 histography in patients with advanced head and neck cancer. Strahlenther. Onkol. 2001, 177:462-468.
137. Sato J., Kitagawa Y., Yamazaki Y., et al. 18-F-fluoromisonidazole PET uptake is correlated with hypoxia-inducible factor-1α expression in oral squamous cell carcinoma. J. Nucl. Med. 2013, 54:1060-1065.
138. Seddon B.M., Maxwell R.J., Honess D.J., et al. Validation of the fluorinated 2-nitroimidazole SR-4554 as a noninvasive hypoxia marker detected by magnetic resonance spectroscopy. Clin. Cancer Res. 2002, 8:2323-2335.
139. Seiwert T.Y., Salama J.K., Vokes E.E. The chemoradiation paradigm in head and neck cancer. Nat. Clin. Pract. Oncol. 2007, 4:156-171.
140. Semenza G.L. Hypoxia, clonal selection, and the role of HIF-1 in tumor progression. Crit. Rev. Biochem. Mol. Biol. 2000, 35:71-103.
141. Sequist L.V., Gettinger S., Senzer N.N., et al. Activity of IPI-504, a novel heat-shock protein 90 inhibitor, in patients with molecularly defined non-small cell lung cancer. J. Clin. Oncol. 2010, 28:4953-4960.
142. Siemens D.R., Hu N., Sheikhi A.K., et al. Hypoxia increases tumor cell shedding of MHC class I chain-related molecule: role of nitric oxide. Cancer Res. 2008, 68:4746-4753.
143. Sitkovsky M.V., Ohta A. The 'danger' sensors that STOP the immune response: the A2 adenosine receptors?. Trends Immunol. 2005, 26:299-304.
144. Sitkovsky M.V., Kjaergaard J., Lukashev D., et al. Hypoxia-adenosinergic immunosuppression: tumor protection by T regulatory cells and cancerous tissue hypoxia. Clin. Cancer Res. 2008, 14:5947-5952.
145. Solit D.B., Osman I., Polsky D., et al. Phase II trial of 17-allylamino-17-demethoxygeldanamycin in patients with metastatic melanoma. Clin. Cancer Res. 2008, 14:8302-8307.
146. 18F]FAZA PET in head and neck cancer patients: a pilot study. Eur. J. Nucl. Med. Mol. Imaging 2007, 34:1566-1575.
147. Stewart D.J., Dahrouge S., Agboola O., et al. Cranial radiation and concomitant cisplatin and mitomycin-C plus resistance modifiers for malignant gliomas. J. Neurooncol. 1997, 32:161-168.
148. Stuben G., Pottgen C., Knuhmann K., et al. Erythropoietin restores the anemia-induced reduction in radiosensitivity of experimental human tumors in nude mice. Int. J. Radiat. Oncol. Biol. Phys. 2003, 55:1358-1362.
149. Suh D.H., Kim M.K., Kim H.S., et al. Unfolded protein response to autophagy as a promising druggable target for anticancer therapy. Ann. N. Y. Acad. Sci. 2012, 1271:20-32.
150. Tang X., Zhang Q., Nishitani J., et al. Overexpression of human papilloma virus type 16 oncoproteins enhances hypoxia-inducible factor 1 alpha protein accumulation and vascular endothelial growth factor expression in human cervical carcinoma cells. Clin. Cancer Res. 2007, 13:2568-2576.
151. Tobin D.A. Explosive decompression in a hyperbaric oxygen chamber. Am. J. Roentgenol. Radium Ther. Nucl. Med. 1971, 111:622-624.
152. Toustrup K., Sorensen B.S., Nordsmark M., et al. Development of a hypoxia gene expression classifier with predictive impact for hypoxic modification of radiotherapy in head and neck cancer. Cancer Res. 2011, 71:5923-5931.
153. Treins C., Giorgetti-Peraldi S., Murdaca J., et al. Insulin stimulates hypoxia-inducible factor 1 through a phosphatidylinositol 3-kinase/target of rapamycin-dependent signaling pathway. J. Biol. Chem. 2002, 277:27975-27981.
154. Trinkaus M.E., Hicks R.J., Young R.J., et al. Correlation of HPV status and hypoxic imaging using [18F]-misonidazole (FMISO) PET in head and neck squamous cell carcinoma (HNSCC). J. Clin. Oncol. 2011, 29:5527.
155. Urtasun R., Band P., Chapman J.D., et al. Radiation and high dose metronidazole in supratentorial glioblastomas. N. Engl. J. Med. 1976, 294:1364-1367.
156. Valdagni R., Amichetti M. Report of long-term follow-up in a randomized trial comparing radiation therapy and radiation therapy plus hyperthermia to metastatic lymph nodes in Stage IV head and neck patients. Int. J. Radiat. Oncol. Biol. Phys. 1993, 28:163-168.
157. Varga Z., de Muler P., Kruit W., et al. A prospective open-label single-arm phase II study of chimeric monoclonal antibody cG250 in advanced renal cell carcinoma patients. Folia Biol. (Praha) 2003, 49:74-77.
158. Vigneswaran N., Wu J., Song A., et al. Hypoxia-induced autophagic response is associated with aggressive phenotype and elevated incidence of metastasis in orthotopic immunocompetent murine models of head and neck squamous cell carcinomas (HNSCC). Exp. Mol. Pathol. 2011, 90:215-225.
159. Ward A., Clissold S.P. Pentoxifylline A review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic efficacy. Drugs 1987, 34:50-97.
160. Webb S.D., Owen M.R., Byrne H.M., et al. Macrophage-based anti-cancer therapy: modelling different modes of tumour targeting. Bull Mat Biol. 2007, 69:1747-1776.
161. Williams K.J., Telfer B.A., Shannon A.M., et al. Combining radiotherapy with AZD2171, a potent inhibitor of vascular endothelial growth factor signaling: pathophysiologic effects and therapeutic benefit. Mol. Cancer Ther. 2007, 6:599-606.
162. Wilson W.R., Hay M.P. Targeting hypoxia in cancer therapy. Nat. Rev. Cancer 2011, 11:393-410.
163. Wilson W.R., Li A.E., Cowan D.S., et al. Enhancement of tumor radiation response by the antivascular agent 5,6-dimethylxanthenone-4-acetic acid. Int. J. Radiat. Oncol. Biol. Phys. 1998, 42:905-908.
164. Wouters B.G., Brown J.M. Cells at intermediate oxygen levels can be more important than the hypoxic fraction in determining tumor response to fractionated radiotherapy. Radiat. Res. 1997, 147:541-550.
165. Wouters B.G., Koritzinsky M. Hypoxia signalling through mTOR and the unfolded protein response in cancer. Nat. Rev. Cancer 2008, 8:851-864.
166. Wu H., Huang S., Zhang D. Autophagic responses to hypoxia and anticancer therapy in head and neck cancer. Pathol. Res. Pract. 2015, 211:101-108.
167. Yankeelov T.E., Gore J.C. Dynamic contrast enhanced magnetic resonance imaging in oncology: theory, data acquisition, analysis and examples. Curr Med Imaging. 2009, 3:91-107.
168. Yu K., Shi C., Toral-Barza L., et al. Beyond rapalog therapy: preclinical pharmacology and antitumor activity of WYE-125132, an ATP-competitive and specific inhibitor of mTORC1 and mTORC2. Cancer Res. 2010, 70:621-631.
169. Zeman E.M. Biologic basics of radiation oncology. Clinical Radiation Oncology 2009, 3-46. Churchill Livingstone, Philadelphia. L.L. Gunderson, J.E. Tepper (Eds.).
170. Zhong H., Chiles K., Feldser D., et al. Modulation of hypoxia-inducible factor 1alpha expression by the epidermal growth factor/phosphatidylinositol/PTEN/AKT/FRAP pathway in human prostate cancer cells: implications for tumor angiogenesis and therapeutics. Cancer Res. 2000, 60:1541-1545.